ACUMEN PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.94 USD | -1.34% |
|
-13.53% | -23.44% |
Presenter SpeechJason Zemansky (Analysts)Well, good morning, everyone. My name is Jason Zemans...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimerâs pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.
Calendar
04/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.94
USD
Average target price
12.8
USD
Spread / Average Target
+335.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.44% | 18Cr | |
| +43.36% | 5.46TCr | |
| -5.31% | 3.99TCr | |
| +37.52% | 3.88TCr | |
| +14.75% | 2.69TCr | |
| -12.56% | 2.62TCr | |
| -22.45% | 1.88TCr | |
| +0.04% | 1.22TCr | |
| +25.12% | 1.22TCr | |
| +26.04% | 1.19TCr |
- Stock Market
- Equities
- ABOS Stock
- News Acumen Pharmaceuticals, Inc.
- Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08
